Acorda Therapeutics Announces Positive Data From Second Phase 3 Study Of Fampridine-SR On Walking Ability In People With Multiple Sclerosis
Acorda Therapeutics, Inc. (NASDAQ: ACOR) announced positive results from its second Phase 3 clinical trial of Fampridine-SR (MS-F204) on walking ability in people with multiple sclerosis (MS). A significantly greater proportion of people taking Fampridine-SR in the trial had a consistent improvement in walking speed compared to people taking placebo (42.
KanekaQ10 trade; To Be Used In Phase III Clinical Trial On Coenzyme Q10's Effects On Huntington's Disease
The Huntington Study Group has launched a Phase III clinical trial, funded by the National Institute of Neurological Disorders and Stroke (part of the National Institutes of Health [NIH]), to determine the effect of the maximum effective dosage of Coenzyme Q10 on cognitive function in individuals with Huntington's Disease (HD).
Rexahn Pharmaceuticals Initiates Phase II Trial For ZoraxelTM To Treat Erectile Dysfunction
Rexahn Pharmaceuticals, Inc. (AMEX:RNN), a biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative treatments for cancer, central nervous system disorders, sexual dysfunction and other unmet medical needs, announced that the Company has initiated a Phase II clinical trial for its lead clinical compound ZoraxelTM, for the treatment of Erectile Dysfunction (ED).
Acucela Doses First Subject In Phase I Trial For Age-Related Macular Degeneration
Acucela Inc., a clinical-stage biotechnology company focused on developing therapies for blinding eye diseases, announced today that it has dosed the first subject in a Phase I trial for its lead compound ACU-02. The single-site trial is enrolling healthy normal volunteers in a double-masked, placebo-controlled, single ascending-dose study to evaluate the safety, tolerability and pharmacokinetics of ACU-02.
TorreyPines Therapeutics Initiates Clinical Trial To Evaluate Analgesic Effect Of Oral Prodrug Of Tezampanel
TorreyPines Therapeutics, Inc. (Nasdaq: TPTX) announced it has initiated a clinical trial to evaluate the analgesic effect of NGX426, the oral prodrug of its lead product candidate, tezampanel. The randomized, double-blind, placebo-controlled Phase I trial will enroll 18 healthy volunteers at a single center in the United States.
Extended Infant Antiretroviral Prophylaxis Reduces HIV Risk During Breastfeeding
In many resource-poor countries, infants born to mothers with HIV receive a single dose of nevirapine (NVP) and a one-week dose of zidovudine (ZDV) to prevent transmission of HIV from the mother to her newborn. The results of a randomized trial led by researchers at the Johns Hopkins Bloomberg School of Public Health and the University of Malawi College of Medicine found that extending the routine antiretroviral regimen can significantly reduce the risk of mother-to-child HIV transmission.
Programs Can Reduce Risky Sex Among HIV Positive Minority Men
Research has shown that HIV-positive African American and Hispanic men who were sexually abused as children are particularly vulnerable to engaging in high-risk sex and experiencing depressive symptoms. Yet few HIV intervention programs exist to help them.
New Diabetes Research To Be Presented At FOCIS Annual Meeting
The Federation of Clinical Immunology Societies (FOCIS) announces the presentation of awards to two researchers recognizing significant findings related to advancement of Type 1 Diabetes research. The awards will be made following a research symposia on June 5, in conjunction with the 8th annual meeting of the Federation of Clinical Immunology Societies (FOCIS), being held at the Boston Marriott Copley Place, June 5-9.
Determining What Outcomes Are Important In Diabetes Trials
According to a study published in the June 4 issue of JAMA, only about 20% of ongoing randomized clinical trials (RCTs) indiabetes consider primary outcomes that patients find important-notably illness, pain, effecton function, and death.Gunjan Y. Gandhi, M.
ViroDefense Inc Announces Selection Of Poliovirus Antiviral Preclinical Candidate
ViroDefense Inc announced that it has chosen to advance a compound licensed to ViroDefense Inc by Schering-Plough Corporation into IND-enabling preclinical studies for the prevention and treatment of poliovirus infections. Schering-Plough licensed to ViroDefense Inc the exclusive rights for development of a specific compound series for polio indications.